TherapeuticsMD Inc
NASDAQ:TXMD
TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 416 full-time employees. The company went IPO on 2001-01-31. Its contraceptive products include ANNOVERA. ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its prenatal vitamin products include vitaTrue, vitaPearl, and BocaGreenMD Prena1 True.
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 416 full-time employees. The company went IPO on 2001-01-31. Its contraceptive products include ANNOVERA. ANNOVERA (segesterone acetate (SA) and ethinyl estradiol (EE) vaginal system) is a one-year ring-shaped contraceptive vaginal system (CVS) and patient-controlled, procedure-free, reversible prescription contraceptive. Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. (estradiol and progesterone) capsules is a bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. Its prenatal vitamin products include vitaTrue, vitaPearl, and BocaGreenMD Prena1 True.
Revenue Growth: TherapeuticsMD reported Q2 revenue of $28.6 million, up 24% from the same period last year.
Cost Control: Operating expenses declined by 21% year-over-year, reflecting tight expense management and the divestiture of vitaCare.
Debt Reduction: The company repaid $120 million in debt during the quarter, primarily funded by the $142.6 million sale of vitaCare.
ANNOVERA Strength: ANNOVERA sales and prescriptions showed strong growth after resolving inventory shortages and receiving FDA approval for expanded supply.
Strategic Alternatives: A planned sale to EW Healthcare Partners fell through due to insufficient shareholder support; management is now exploring refinancing and other strategic options.
Liquidity Actions: TherapeuticsMD secured a $15 million investment and extended debt maturity to support near-term operations.
